MRI features after prostatic artery embolization for the treatment of medium- and large-volume benign hyperplasia
To assess magnetic resonance imaging (MRI) features after prostatic artery embolization (PAE) for the treatment of medium- and large-volume benign prostatic hyperplasia and to correlate prostate volume with clinical indexes.
We retrospectively evaluated 28 patients who underwent PAE. MRI examinations of the prostate were performed to evaluate signal intensity changes and the characteristics of infarcted areas. Prostate volume and the apparent diffusion coefficient (ADC) were measured at an average of 10 days post-PAE and at 1, 3, 6, and 12 months post-PAE. Some clinical indexes were evaluated before and 12 months after PAE. The paired t test, ANOVA, and multiple linear correlation analyses were performed by using the statistical software, SPSS.
All patients experienced prostatic infarction. The prostate volume decreased continuously (p < 0.05). The ADC values before and after 1, 3, 6, or 12 months of embolization (b = 1000 and 2000 s/mm2) were statistically significantly different. The ADC values (b = 3000 s/mm2) were also statistically significantly different before and at each interval time after embolization (p < 0.05). Prostate volume changes correlated significantly with patient age and post-void residual urine volume (p < 0.05).
MRI can be used for assessing changes in signal intensity and ADC values of infarction as well as the volume of the prostate after PAE. After PAE, ultrahigh b value diffusion-weighted imaging (DWI) can show early infarction better than lower b value DWI.
KeywordsMagnetic resonance imaging Prostatic hyperplasia Embolization Therapeutic Diffusion magnetic resonance imaging Infarction
This study has received funding by the Health Care Special Project (14BJZ02) and National Natural Science Foundation of China (No. 81771785).
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
This article does not contain any studies with human participants performed by any of the authors. Each author has participated sufficiently in any submission to take public responsibility for its content. All procedures were performed in accordance with ethical standards of the Declaration of Helsinki. The study was approved by the hospital ethical committee. Written informed consent was obtained from each patient.
- 12.Little MW, Boardman P, Macdonald AC, Taylor N, Macpherson R, Crew J et al (2017) Adenomatous-dominant benign prostatic hyperplasia (AdBPH) as a predictor for clinical success following prostate artery embolization: an age-matched case-control study. Cardiovasc Intervent Radiol 40:682–689CrossRefGoogle Scholar
- 22.Hausmann D, Aksöz N, von Hardenberg J, Martini T, Westhoff N, Buettner S et al (2018) Prostate cancer detection among readers with different degree of experience using ultra-high b-value diffusion-weighted Imaging: Is a non-contrast protocol sufficient to detect significant cancer? Eur Radiol 28:869–876CrossRefGoogle Scholar
- 26.Pisco JM, Rio Tinto H, Campos Pinheiro L, Bilhim T, Duarte M, Fernandes L et al (2013) Embolisation of prostatic arteries as treatment of moderate to severe lower urinary symptoms (LUTS) secondary to benign hyperplasia: results of short- and mid-term follow-up. Eur Radiol 23:2561–2572CrossRefGoogle Scholar
- 30.Bilhim T, Pisco J, Pereira JA, Costa NV, Fernandes L, Campos Pinheiro L et al (2016) Predictors of clinical outcome after prostate artery embolization with spherical and nonspherical polyvinyl alcohol particles in patients with benign prostatic hyperplasia. Radiology 281:289–300CrossRefGoogle Scholar